Vanda Pharmaceuticals Inc Earnings
The next earnings date for Vanda Pharmaceuticals Inc is November 4, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Vanda Pharmaceuticals Inc Earnings
| 11/04/2026 | $-0.72 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Vanda Pharmaceuticals Inc Earnings: Historical
| 08/05/2026 | After Market | $-1.04 | -103.92% |
| 05/06/2026 | After Market | $-0.82 | -18.84% |
| 02/11/2026 | After Market | $-2.39 | -81.06% |
| 10/29/2025 | After Market | $-0.38 | 15.56% |
| 07/31/2025 | Before Market | $-0.46 | -27.78% |
| 05/07/2025 | After Market | $-0.50 | 16.67% |
| 02/13/2025 | After Market | $-0.08 | 27.27% |
| 11/06/2024 | After Market | $-0.09 | 43.75% |
| 07/31/2024 | After Market | $-0.08 | 61.90% |
| 05/09/2024 | Before Market | $-0.07 | -240.00% |
More About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
“Vanda Pharmaceuticals Inc Earnings” Can Refer to the Vanda Pharmaceuticals Inc Earnings Date
Some people say “Vanda Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Vanda Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Vanda Pharmaceuticals Inc Stock on the Earnings Date
If you own Vanda Pharmaceuticals Inc stock (VNDA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Vanda Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Vanda Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Vanda Pharmaceuticals Inc Earnings
You can contact us any time if you would like to ask questions about Vanda Pharmaceuticals Inc earnings or anything else related to the stock market.